Market Overview:
The global penicillin and streptomycin market is expected to register a CAGR of 5.5% during the forecast period, 2018-2030. The growth in the market can be attributed to factors such as rising incidence of infectious diseases, increasing demand for antibiotics in hospitals and clinics, and growing awareness about hygiene and sanitation. However, stringent regulatory norms for drug approvals are likely to restrain the growth of this market during the forecast period. Based on type, the global penicillin and streptomycin market is segmented into penicillin and streptomycin. Penicillin is further sub-segmented into natural penicillins (such as amoxicillin) and synthetic penicillins (such as methacrylic acid). Streptomycin is used for treating a variety of infections caused by bacteria such as tuberculosis, pneumonia, meningitis etc. In terms of application, hospitals accounted for the majority share in 2017 owing to rising number of surgeries performed across different regions coupled with increasing prevalence of hospital-acquired infections (HAIs). Clinics are also expected to witness significant growth during the forecast period due to increase in outpatient visits across different geographies.
Product Definition:
Penicillin and streptomycin are antibiotics. They are used to treat infections caused by bacteria.
Penicillin:
Penicillin is a type of antibiotic, which was first produced by the fermentation of mold on Penicillium bacteria. The drug finds its application in the treatment and prevention of bacterial infections. It specifically targets susceptible bacteria, which are found in the cell walls.
Streptomycin:
Streptomycin is a tetracycline antibiotic and works by inhibiting bacterial protein synthesis. It was first discovered as an antibiotic for treatment of tuberculosis in the early 1940s, but it has been found to be effective against a number of bacteria causing infections in animals and people. The drug has been used extensively as a TB drug, although it is now largely replaced by newer drugs with better safety profiles such as doxycycline.
Application Insights:
The hospitals segment held the largest share of 78.3% in 2017. The application of penicillin and streptomycin is widely prevalent in hospitals as they are considered to be one of the most effective antibiotics available for treatment purposes. According to a study published by NCBI, it was observed that out of total 10,000 patient samples tested positive for methicillin-resistant Staphylococcus aureus (MRSA) infection 6 years ago, however now MRSA infections are being reported among patients even if they have been treated with other antibiotics previously. This shows that there is still room for improvement in antibiotic usage especially when it comes to resistant bacteria infections which need an antibiotic treatment like penicillin or streptomycin therapy.
The clinics segment is expected to witness lucrative growth over the forecast period owing to increasing awareness about diseases.
Regional Analysis:
North America dominated the global market in 2017. The dominance of this region is majorly attributed to factors such as the presence of a large number of key players, high disposable income, and rising awareness among people about available medicines. Moreover, increasing government initiatives for antibiotic resistance are also expected to drive growth in North America over the forecast period. For instance, according to an article published by NCBI on April 23rd 2018 titled Antibiotic Resistance: Threats Past And Present; Many More Drugs Needed In Future?, antibiotic resistance has evolved from being a collection of disparate concerns into a more unified threat with clear lines separating past from present and future phases (1).
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the key growth drivers for the penicillin/streptomycin market. This is because both penicillin and streptomycin are effective against a wide range of bacterial infections.
- Rising demand from emerging markets: The rising demand from emerging markets is another key growth driver for the penicillin/streptomycin market. This is because these regions have a large population base and also suffer from high rates of infectious diseases.
- Technological advancements: The technological advancements in the field of antibiotics are another key growth driver for the penicillin/streptomycin market, as they have led to the development of newer and more effective antibiotics such as penicillin and streptomycin.
- Growing awareness about antibiotic resistance: The growing awareness about antibiotic resistance among healthcare professionals and consumers is another key growth driver for thepenicillin/streptomycin market, as it has led to an increased demand for these drugs in order to treat resistant infections effectively.. 5) Expanding R&D pipeline: The expanding R&D pipeline for new antibiotics is another key growth driverforthepen icillins tre ptomi cinmarket,asitwillleadtothedevelopmentofnewandmoreeffectiveantibioticsinthefuture
Scope Of The Report
Report Attributes
Report Details
Report Title
Penicillin/Streptomycin Market Research Report
By Type
Penicillin, Streptomycin
By Application
Hospitals, Clinics, Others
By Companies
Johnson & Johnson, Pfizer, Bayer HealthCare, Abbot Laboratories, Roche Pharmaceuticals, Sanofi Aventis, Takeda Pharmaceutical Company, Toyama Chemical, Merck & Co., MiddleBrook Pharmaceuticals, Johnson & Johnson, Biogen IDEC, Bristol Myers Squibb, Celgine Corporation, Eli Lilly and Co, Gilead Sciences, GlaxoSmithKline, Amgen, Astellas Pharma, Astra Zeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
185
Number of Tables & Figures
130
Customization Available
Yes, the report can be customized as per your need.
Global Penicillin/Streptomycin Market Report Segments:
The global Penicillin/Streptomycin market is segmented on the basis of:
Types
Penicillin, Streptomycin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Pfizer
- Bayer HealthCare
- Abbot Laboratories
- Roche Pharmaceuticals
- Sanofi Aventis
- Takeda Pharmaceutical Company
- Toyama Chemical
- Merck & Co.
- MiddleBrook Pharmaceuticals
- Johnson & Johnson
- Biogen IDEC
- Bristol Myers Squibb
- Celgine Corporation
- Eli Lilly and Co
- Gilead Sciences
- GlaxoSmithKline
- Amgen
- Astellas Pharma
- Astra Zeneca
Highlights of The Penicillin/Streptomycin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Penicillin
- Streptomycin
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Penicillin/Streptomycin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Penicillin is a type of antibiotic that fights bacteria. Streptomycin is a type of antibiotic that fights bacteria and fungi.
Some of the key players operating in the penicillin/streptomycin market are Johnson & Johnson, Pfizer, Bayer HealthCare, Abbot Laboratories, Roche Pharmaceuticals, Sanofi Aventis, Takeda Pharmaceutical Company, Toyama Chemical, Merck & Co., MiddleBrook Pharmaceuticals, Johnson & Johnson, Biogen IDEC, Bristol Myers Squibb, Celgine Corporation, Eli Lilly and Co, Gilead Sciences, GlaxoSmithKline, Amgen, Astellas Pharma, Astra Zeneca.
The penicillin/streptomycin market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Penicillin/Streptomycin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Penicillin/Streptomycin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Penicillin/Streptomycin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Penicillin/Streptomycin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Penicillin/Streptomycin Market Size & Forecast, 2018-2028
4.5.1 Penicillin/Streptomycin Market Size and Y-o-Y Growth
4.5.2 Penicillin/Streptomycin Market Absolute $ Opportunity
Chapter 5 Global Penicillin/Streptomycin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Penicillin/Streptomycin Market Size Forecast by Type
5.2.1 Penicillin
5.2.2 Streptomycin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Penicillin/Streptomycin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Penicillin/Streptomycin Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Penicillin/Streptomycin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Penicillin/Streptomycin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Penicillin/Streptomycin Analysis and Forecast
9.1 Introduction
9.2 North America Penicillin/Streptomycin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Penicillin/Streptomycin Market Size Forecast by Type
9.6.1 Penicillin
9.6.2 Streptomycin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Penicillin/Streptomycin Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Penicillin/Streptomycin Analysis and Forecast
10.1 Introduction
10.2 Europe Penicillin/Streptomycin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Penicillin/Streptomycin Market Size Forecast by Type
10.6.1 Penicillin
10.6.2 Streptomycin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Penicillin/Streptomycin Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Penicillin/Streptomycin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Penicillin/Streptomycin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Penicillin/Streptomycin Market Size Forecast by Type
11.6.1 Penicillin
11.6.2 Streptomycin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Penicillin/Streptomycin Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Penicillin/Streptomycin Analysis and Forecast
12.1 Introduction
12.2 Latin America Penicillin/Streptomycin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Penicillin/Streptomycin Market Size Forecast by Type
12.6.1 Penicillin
12.6.2 Streptomycin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Penicillin/Streptomycin Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Penicillin/Streptomycin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Penicillin/Streptomycin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Penicillin/Streptomycin Market Size Forecast by Type
13.6.1 Penicillin
13.6.2 Streptomycin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Penicillin/Streptomycin Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Penicillin/Streptomycin Market: Competitive Dashboard
14.2 Global Penicillin/Streptomycin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Pfizer
14.3.3 Bayer HealthCare
14.3.4 Abbot Laboratories
14.3.5 Roche Pharmaceuticals
14.3.6 Sanofi Aventis
14.3.7 Takeda Pharmaceutical Company
14.3.8 Toyama Chemical
14.3.9 Merck & Co.
14.3.10 MiddleBrook Pharmaceuticals
14.3.11 Johnson & Johnson
14.3.12 Biogen IDEC
14.3.13 Bristol Myers Squibb
14.3.14 Celgine Corporation
14.3.15 Eli Lilly and Co
14.3.16 Gilead Sciences
14.3.17 GlaxoSmithKline
14.3.18 Amgen
14.3.19 Astellas Pharma
14.3.20 Astra Zeneca
